Study: GENERATION HD1

Study title: A Randomized, Multicenter, Double-Blind, Placebo-Controlled, Phase III Clinical Study to Evaluate the Efficacy and Safety of Intrathecally Administered RO7234292 (RG6042) in Patients With Manifest Huntington's Disease

Substance: Tominersen RO7234292 (RG6042)

EudraCT NO: 2018-003898-94

Objective: To evaluate efficacy, safety and biomarker effects of RO7234292 (RG6042) compared to placebo in patients (25-65 years) with manifest Huntington's disease.

Start: January 2019, recruitment completed

Further information: https://clinicaltrials.gov/ct2/show/NCT03761849

Morbus Huntington

Studie: GENERATION HD1

Studientitel: A Randomized, Multicenter, Double-Blind, Placebo-Controlled, Phase III Clinical Study to Evaluate the Efficacy and Safety of Intrathecally Administered RO7234292 (RG6042) in Patients With Manifest Huntington's Disease

Substanz: Tominersen RO7234292 (RG6042)

EudraCT NO: 2018-003898-94

Ziel: Beurteilung von Wirksamkeit, Sicherheit und Biomarkereffekten von RO7234292 (RG6042) im Vergleich mit Placebo bei Patienten (25-65 Jahre) mit manifester Huntington Erkrankung.

Beginn: Januar 2019, Rekrutierung abgeschlossen

Weitere Informationen:
https://clinicaltrials.gov/ct2/show/NCT03761849